1 | secretion | 4,923 |
2 | glargine | 1,073 |
3 | detemir | 382 |
4 | aspart | 284 |
5 | lispro | 270 |
6 | 761 | 178 |
7 | sensitizer | 164 |
8 | sensitizers | 138 |
9 | hypersecretion | 133 |
10 | degludec | 131 |
11 | glulisine | 97 |
12 | pulmonale | 94 |
13 | secretagogue | 66 |
14 | secretagogues | 49 |
15 | 70/30 | 48 |
16 | trap-eye | 47 |
17 | sensitisers | 32 |
18 | isophane | 26 |
19 | 75/25 | 20 |
20 | 761® | 14 |
21 | a/d | 13 |
22 | biomagnification | 10 |
23 | ultralente | 10 |
24 | 1-75 | 9 |
25 | sensitiser | 9 |
26 | 761r | 8 |
27 | er-c | 8 |
28 | 39758979 | 7 |
29 | arg194trp | 7 |
30 | 15850a | 6 |
31 | le-1 | 6 |
32 | 7421 | 5 |
33 | oxabifore | 5 |
34 | rs10004195 | 5 |
35 | 0.0215-in | 4 |
36 | 1b3 | 4 |
37 | cdri-08 | 4 |
38 | co-therapies | 4 |
39 | degludec/insulin | 4 |
40 | fldl | 4 |
41 | imvi | 4 |
42 | io-curve | 4 |
43 | mycotoxicosis | 4 |
44 | rs2317676 | 4 |
45 | rs693 | 4 |
46 | -auc0-24hr | 3 |
47 | autofeedback | 3 |
48 | cis-9,12,15 | 3 |
49 | glargine-only | 3 |
50 | hyper-secretion | 3 |
51 | resistance-index | 3 |
52 | resistance/hyperinsulinemia | 3 |
53 | secretagogs | 3 |
54 | secretion/insulin | 3 |
55 | spirilloxanthin | 3 |
56 | triatriatum | 3 |
57 | +3954 | 2 |
58 | -799c | 2 |
59 | 1,25-dihydroxyvitamin-d | 2 |
60 | 10-plex | 2 |
61 | 4-oxide | 2 |
62 | a.m.+psychostimulant | 2 |
63 | acrp30 | 2 |
64 | concentration-to-rate | 2 |
65 | degludec/liraglutide | 2 |
66 | detemir-nph | 2 |
67 | f-340 | 2 |
68 | humidifier™ | 2 |
69 | interferon‑γ | 2 |
70 | kofta | 2 |
71 | lispro+bedtime | 2 |
72 | neurosporene | 2 |
73 | p.m.+psychostimulant | 2 |
74 | pen-experienced | 2 |
75 | phenylpropyl | 2 |
76 | protamine-aspart/aspart | 2 |
77 | resistance-induced | 2 |
78 | resistance/diabetes | 2 |
79 | resistance/hyperinsulinaemia | 2 |
80 | resistance/secretion | 2 |
81 | resistance/type | 2 |
82 | resistants | 2 |
83 | rs2076167 | 2 |
84 | rs4553808 | 2 |
85 | sensitivity-related | 2 |
86 | uacc-62 | 2 |
87 | µmol/g/min | 2 |
88 | -25.4/hour | 1 |
89 | 2.2mg/kg | 1 |
90 | 241385 | 1 |
91 | 27.5±3.1u | 1 |
92 | 2·2-2·4-fold | 1 |
93 | 3-iodobutenolides | 1 |
94 | 3/4-bromo-n'- | 1 |
95 | 61+/-1 | 1 |
96 | 63545820 | 1 |
97 | 9.8±9.5 | 1 |
98 | actvity | 1 |
99 | analogs-insulin | 1 |
100 | antagonsists | 1 |
101 | ba2au6 | 1 |
102 | bound/dl | 1 |
103 | bronchodilator/anti-inflammatory | 1 |
104 | concentrations-after | 1 |
105 | concentrations/production | 1 |
106 | debranches | 1 |
107 | degludec-liraglutide | 1 |
108 | desoxycytidine | 1 |
109 | detemir-offer | 1 |
110 | detemir/nph | 1 |
111 | dling | 1 |
112 | empordà | 1 |
113 | excess/disorders | 1 |
114 | expression/secretion | 1 |
115 | glargin | 1 |
116 | glargine-to-total | 1 |
117 | glargine/insulin | 1 |
118 | godal | 1 |
119 | gustducin-expressing | 1 |
120 | hyperincretion | 1 |
121 | hypersecretion-suppressive | 1 |
122 | hyposensitiveness | 1 |
123 | i341f/i534r | 1 |
124 | ii-dots-1 | 1 |
125 | infusion-treated | 1 |
126 | intensified-dc | 1 |
127 | ligand-5 | 1 |
128 | load±a | 1 |
129 | madarasepatana | 1 |
130 | methacin | 1 |
131 | mh4l3 | 1 |
132 | micro-/nanoparticles | 1 |
133 | nanocluster-pmma | 1 |
134 | nanotherapies | 1 |
135 | ortnf-alpha | 1 |
136 | p=.749 | 1 |
137 | peak/fsh | 1 |
138 | peglispro | 1 |
139 | phosphatidyl-inositol | 1 |
140 | phototransformation | 1 |
141 | pump-naive | 1 |
142 | resistance-evoking | 1 |
143 | resistance-hepatic | 1 |
144 | resistance-hyperinsulinaemia | 1 |
145 | resistant-hypertensive | 1 |
146 | riet | 1 |
147 | rs10948751 | 1 |
148 | rs12327666 | 1 |
149 | rs12568757 | 1 |
150 | rα | 1 |
151 | secretalogue | 1 |
152 | secretion/ir | 1 |
153 | secretionn | 1 |
154 | sencitivity | 1 |
155 | sensitivity.we | 1 |
156 | sensitivity/secretion | 1 |
157 | sensitizer-thiazolidinediones | 1 |
158 | signaling-3-mediated | 1 |
159 | single-epitope | 1 |
160 | sofer | 1 |
161 | tandem-epitope | 1 |
162 | training-groups | 1 |
163 | tycf | 1 |
164 | u1111-1124-0244 | 1 |
165 | u1111-1129-9629 | 1 |
166 | underdelivery | 1 |
167 | up-modulates | 1 |
168 | winehouse | 1 |
169 | ≥2.5μg/l | 1 |
170 | ≥204 | 1 |
1 | +3954 | 2 |
2 | -25.4/hour | 1 |
3 | -799c | 2 |
4 | -auc0-24hr | 3 |
5 | 0.0215-in | 4 |
6 | 1,25-dihydroxyvitamin-d | 2 |
7 | 1-75 | 9 |
8 | 10-plex | 2 |
9 | 15850a | 6 |
10 | 1b3 | 4 |
11 | 2.2mg/kg | 1 |
12 | 241385 | 1 |
13 | 27.5±3.1u | 1 |
14 | 2·2-2·4-fold | 1 |
15 | 3-iodobutenolides | 1 |
16 | 3/4-bromo-n'- | 1 |
17 | 39758979 | 7 |
18 | 4-oxide | 2 |
19 | 61+/-1 | 1 |
20 | 63545820 | 1 |
21 | 70/30 | 48 |
22 | 7421 | 5 |
23 | 75/25 | 20 |
24 | 761 | 178 |
25 | 761r | 8 |
26 | 761® | 14 |
27 | 9.8±9.5 | 1 |
28 | a.m.+psychostimulant | 2 |
29 | a/d | 13 |
30 | acrp30 | 2 |
31 | actvity | 1 |
32 | analogs-insulin | 1 |
33 | antagonsists | 1 |
34 | arg194trp | 7 |
35 | aspart | 284 |
36 | autofeedback | 3 |
37 | ba2au6 | 1 |
38 | biomagnification | 10 |
39 | bound/dl | 1 |
40 | bronchodilator/anti-inflammatory | 1 |
41 | cdri-08 | 4 |
42 | cis-9,12,15 | 3 |
43 | co-therapies | 4 |
44 | concentration-to-rate | 2 |
45 | concentrations-after | 1 |
46 | concentrations/production | 1 |
47 | debranches | 1 |
48 | degludec | 131 |
49 | degludec-liraglutide | 1 |
50 | degludec/insulin | 4 |
51 | degludec/liraglutide | 2 |
52 | desoxycytidine | 1 |
53 | detemir | 382 |
54 | detemir-nph | 2 |
55 | detemir-offer | 1 |
56 | detemir/nph | 1 |
57 | dling | 1 |
58 | empordà | 1 |
59 | er-c | 8 |
60 | excess/disorders | 1 |
61 | expression/secretion | 1 |
62 | f-340 | 2 |
63 | fldl | 4 |
64 | glargin | 1 |
65 | glargine | 1,073 |
66 | glargine-only | 3 |
67 | glargine-to-total | 1 |
68 | glargine/insulin | 1 |
69 | glulisine | 97 |
70 | godal | 1 |
71 | gustducin-expressing | 1 |
72 | humidifier™ | 2 |
73 | hyper-secretion | 3 |
74 | hyperincretion | 1 |
75 | hypersecretion | 133 |
76 | hypersecretion-suppressive | 1 |
77 | hyposensitiveness | 1 |
78 | i341f/i534r | 1 |
79 | ii-dots-1 | 1 |
80 | imvi | 4 |
81 | infusion-treated | 1 |
82 | intensified-dc | 1 |
83 | interferon‑γ | 2 |
84 | io-curve | 4 |
85 | isophane | 26 |
86 | kofta | 2 |
87 | le-1 | 6 |
88 | ligand-5 | 1 |
89 | lispro | 270 |
90 | lispro+bedtime | 2 |
91 | load±a | 1 |
92 | madarasepatana | 1 |
93 | methacin | 1 |
94 | mh4l3 | 1 |
95 | micro-/nanoparticles | 1 |
96 | mycotoxicosis | 4 |
97 | nanocluster-pmma | 1 |
98 | nanotherapies | 1 |
99 | neurosporene | 2 |
100 | ortnf-alpha | 1 |
101 | oxabifore | 5 |
102 | p.m.+psychostimulant | 2 |
103 | p=.749 | 1 |
104 | peak/fsh | 1 |
105 | peglispro | 1 |
106 | pen-experienced | 2 |
107 | phenylpropyl | 2 |
108 | phosphatidyl-inositol | 1 |
109 | phototransformation | 1 |
110 | protamine-aspart/aspart | 2 |
111 | pulmonale | 94 |
112 | pump-naive | 1 |
113 | resistance-evoking | 1 |
114 | resistance-hepatic | 1 |
115 | resistance-hyperinsulinaemia | 1 |
116 | resistance-index | 3 |
117 | resistance-induced | 2 |
118 | resistance/diabetes | 2 |
119 | resistance/hyperinsulinaemia | 2 |
120 | resistance/hyperinsulinemia | 3 |
121 | resistance/secretion | 2 |
122 | resistance/type | 2 |
123 | resistant-hypertensive | 1 |
124 | resistants | 2 |
125 | riet | 1 |
126 | rs10004195 | 5 |
127 | rs10948751 | 1 |
128 | rs12327666 | 1 |
129 | rs12568757 | 1 |
130 | rs2076167 | 2 |
131 | rs2317676 | 4 |
132 | rs4553808 | 2 |
133 | rs693 | 4 |
134 | rα | 1 |
135 | secretagogs | 3 |
136 | secretagogue | 66 |
137 | secretagogues | 49 |
138 | secretalogue | 1 |
139 | secretion | 4,923 |
140 | secretion/insulin | 3 |
141 | secretion/ir | 1 |
142 | secretionn | 1 |
143 | sencitivity | 1 |
144 | sensitiser | 9 |
145 | sensitisers | 32 |
146 | sensitivity-related | 2 |
147 | sensitivity.we | 1 |
148 | sensitivity/secretion | 1 |
149 | sensitizer | 164 |
150 | sensitizer-thiazolidinediones | 1 |
151 | sensitizers | 138 |
152 | signaling-3-mediated | 1 |
153 | single-epitope | 1 |
154 | sofer | 1 |
155 | spirilloxanthin | 3 |
156 | tandem-epitope | 1 |
157 | training-groups | 1 |
158 | trap-eye | 47 |
159 | triatriatum | 3 |
160 | tycf | 1 |
161 | u1111-1124-0244 | 1 |
162 | u1111-1129-9629 | 1 |
163 | uacc-62 | 2 |
164 | ultralente | 10 |
165 | underdelivery | 1 |
166 | up-modulates | 1 |
167 | winehouse | 1 |
168 | µmol/g/min | 2 |
169 | ≥2.5μg/l | 1 |
170 | ≥204 | 1 |
1 | 3/4-bromo-n'- | 1 |
2 | 63545820 | 1 |
3 | 70/30 | 48 |
4 | acrp30 | 2 |
5 | f-340 | 2 |
6 | 61+/-1 | 1 |
7 | le-1 | 6 |
8 | ii-dots-1 | 1 |
9 | 7421 | 5 |
10 | rs10948751 | 1 |
11 | 761 | 178 |
12 | uacc-62 | 2 |
13 | rs693 | 4 |
14 | 1b3 | 4 |
15 | mh4l3 | 1 |
16 | ≥204 | 1 |
17 | u1111-1124-0244 | 1 |
18 | +3954 | 2 |
19 | ligand-5 | 1 |
20 | 9.8±9.5 | 1 |
21 | cis-9,12,15 | 3 |
22 | 75/25 | 20 |
23 | 1-75 | 9 |
24 | 241385 | 1 |
25 | rs10004195 | 5 |
26 | rs12327666 | 1 |
27 | rs2317676 | 4 |
28 | ba2au6 | 1 |
29 | rs12568757 | 1 |
30 | rs2076167 | 2 |
31 | cdri-08 | 4 |
32 | rs4553808 | 2 |
33 | u1111-1129-9629 | 1 |
34 | p=.749 | 1 |
35 | 39758979 | 7 |
36 | 15850a | 6 |
37 | ortnf-alpha | 1 |
38 | resistance-hyperinsulinaemia | 1 |
39 | resistance/hyperinsulinaemia | 2 |
40 | resistance/hyperinsulinemia | 3 |
41 | nanocluster-pmma | 1 |
42 | madarasepatana | 1 |
43 | kofta | 2 |
44 | load±a | 1 |
45 | er-c | 8 |
46 | -799c | 2 |
47 | intensified-dc | 1 |
48 | degludec | 131 |
49 | resistance-hepatic | 1 |
50 | 1,25-dihydroxyvitamin-d | 2 |
51 | a/d | 13 |
52 | pen-experienced | 2 |
53 | resistance-induced | 2 |
54 | infusion-treated | 1 |
55 | signaling-3-mediated | 1 |
56 | sensitivity-related | 2 |
57 | 2·2-2·4-fold | 1 |
58 | degludec-liraglutide | 1 |
59 | degludec/liraglutide | 2 |
60 | 4-oxide | 2 |
61 | pulmonale | 94 |
62 | lispro+bedtime | 2 |
63 | isophane | 26 |
64 | neurosporene | 2 |
65 | desoxycytidine | 1 |
66 | glargine | 1,073 |
67 | glulisine | 97 |
68 | single-epitope | 1 |
69 | tandem-epitope | 1 |
70 | resistance/type | 2 |
71 | oxabifore | 5 |
72 | winehouse | 1 |
73 | concentration-to-rate | 2 |
74 | ultralente | 10 |
75 | secretagogue | 66 |
76 | secretalogue | 1 |
77 | pump-naive | 1 |
78 | resistant-hypertensive | 1 |
79 | hypersecretion-suppressive | 1 |
80 | io-curve | 4 |
81 | sensitivity.we | 1 |
82 | trap-eye | 47 |
83 | tycf | 1 |
84 | 2.2mg/kg | 1 |
85 | resistance-evoking | 1 |
86 | dling | 1 |
87 | gustducin-expressing | 1 |
88 | detemir-nph | 2 |
89 | detemir/nph | 1 |
90 | peak/fsh | 1 |
91 | imvi | 4 |
92 | autofeedback | 3 |
93 | ≥2.5μg/l | 1 |
94 | godal | 1 |
95 | glargine-to-total | 1 |
96 | bound/dl | 1 |
97 | fldl | 4 |
98 | phosphatidyl-inositol | 1 |
99 | phenylpropyl | 2 |
100 | triatriatum | 3 |
101 | 0.0215-in | 4 |
102 | methacin | 1 |
103 | glargin | 1 |
104 | spirilloxanthin | 3 |
105 | analogs-insulin | 1 |
106 | degludec/insulin | 4 |
107 | glargine/insulin | 1 |
108 | secretion/insulin | 3 |
109 | µmol/g/min | 2 |
110 | secretionn | 1 |
111 | biomagnification | 10 |
112 | phototransformation | 1 |
113 | concentrations/production | 1 |
114 | secretion | 4,923 |
115 | hyper-secretion | 3 |
116 | resistance/secretion | 2 |
117 | expression/secretion | 1 |
118 | sensitivity/secretion | 1 |
119 | hypersecretion | 133 |
120 | hyperincretion | 1 |
121 | lispro | 270 |
122 | peglispro | 1 |
123 | arg194trp | 7 |
124 | 761r | 8 |
125 | i341f/i534r | 1 |
126 | detemir-offer | 1 |
127 | sofer | 1 |
128 | sensitiser | 9 |
129 | concentrations-after | 1 |
130 | sensitizer | 164 |
131 | -auc0-24hr | 3 |
132 | secretion/ir | 1 |
133 | detemir | 382 |
134 | -25.4/hour | 1 |
135 | 3-iodobutenolides | 1 |
136 | debranches | 1 |
137 | co-therapies | 4 |
138 | nanotherapies | 1 |
139 | micro-/nanoparticles | 1 |
140 | sensitizer-thiazolidinediones | 1 |
141 | up-modulates | 1 |
142 | resistance/diabetes | 2 |
143 | secretagogues | 49 |
144 | secretagogs | 3 |
145 | mycotoxicosis | 4 |
146 | training-groups | 1 |
147 | excess/disorders | 1 |
148 | sensitisers | 32 |
149 | sensitizers | 138 |
150 | hyposensitiveness | 1 |
151 | resistants | 2 |
152 | antagonsists | 1 |
153 | riet | 1 |
154 | a.m.+psychostimulant | 2 |
155 | p.m.+psychostimulant | 2 |
156 | aspart | 284 |
157 | protamine-aspart/aspart | 2 |
158 | 27.5±3.1u | 1 |
159 | resistance-index | 3 |
160 | 10-plex | 2 |
161 | glargine-only | 3 |
162 | underdelivery | 1 |
163 | bronchodilator/anti-inflammatory | 1 |
164 | sencitivity | 1 |
165 | actvity | 1 |
166 | empordà | 1 |
167 | humidifier™ | 2 |
168 | 761® | 14 |
169 | rα | 1 |
170 | interferon‑γ | 2 |